Company: PRGO
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001585364-25-000122
Chunk: 217

Company: PERRIGO Co plc
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 9
Chunk 217
---
NOTE 9 - FAIR VALUE MEASUREMENTS 

The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):June 28, 2025December 31, 2024Measured at fair value on a recurring basis:Level 1Level 2Level 3Level 1Level 2Level 3Assets:Foreign currency forward contracts$— $7.0 $— $— $5.5 $— Cross-currency swaps— — — — 14.2 — Interest rate swap agreements— 3.5 — — 9.3 — Total assets$— $10.5 $— $— $29.0 $— Liabilities:Foreign currency forward contracts$— $5.8 $— $— $5.6 $— Cross-currency swaps— 273.5 — — 46.8 — Interest rate swap agreements— 34.3 — — 22.6 — Total liabilities$— $313.6 $— $— $75.0 $— Measured at fair value on a non-recurring basis:Assets:Contingent consideration(1) $— $— $— $— $— $34.5 Definite-lived intangible assets(2)— — 5.5 — — 8.2 Total assets$— $— $5.5 $— $— $42.7 (1) During the year ended December 31, 2024, contingent consideration was recognized as a result of the divestiture of the Rare Diseases Business.(2) During the three months ended June 28, 2025, we assessed the fair value of our Prevacid® branded product at $5.5 million, resulting in an asset impairment charge of $1.5 million. During the three months ended December 31, 2024, we assessed the fair value of our Prevacid® branded product at $8.2 million, resulting in an asset impairment charge of $38.6 million.

15

Perrigo Company plc - Item 1Note 9

There were no transfers within Level 3 fair value measurements during the three and six months ended June 28,